Induction of <i>WT1</i> (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

Akihiro Tsuboi, Tetsuya Taguchi, Tadashi Osaki, +22

Proceedings of the National Academy of Sciences

Cytotoxic T LymphocytesWt1 PeptideImmune RegulationImmunologyImmunodominance +22

Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene ( WT1  ) product

Yoshio Oka, Olga A. Elisseeva, Akihiro Tsuboi, +13

Immunogenetics

MedicineT-regulatory CellImmunologyPathologyT-lymphocyte Responses +8

The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia

Hiroyasu Ogawa, Hiroya Tamaki, Kazuhiro Ikegame, +12

Blood

Expression of the Wilms' Tumor Gene <i>WT1</i> in Solid Tumors and Its Involvement in Tumor Cell Growth

Yusuke Oji, Hiroyasu Ogawa, Hiroya Tamaki, +8

Japanese Journal of Cancer Research

Tumor Cell GrowthRadiation OncologyOncologyWt1 GeneSolid Tumors +13

Cancer Immunotherapy Targeting Wilms’ Tumor Gene WT1 Product

Keiko Udaka, Akihiro Tsuboi, Olga A. Elisseeva, +4

The Journal of Immunology

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme

Shuichi Izumoto, Akihiro Tsuboi, Tsuyoshi Suzuki, +18

Journal of neurosurgery

Overexpression of the Wilms' tumor gene <i>WT1</i> in <i>de novo</i> lung cancers

Yusuke Oji, Shinichiro Miyoshi, Hajime Maeda, +22

International Journal of Cancer

The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes

Hiroya Tamaki, Hiroyasu Ogawa, Kazuma Ohyashiki, +16

Leukemia

Hematological MalignancyGood MarkerDisease ProgressionGenetic DisorderMedicine +8

Wilms' Tumor Gene (WT1) Competes With Differentiation-Inducing Signal in Hematopoietic Progenitor Cells

Kazushi Inoue, Hiroya Tamaki, Hiroyasu Ogawa, +9

Blood

The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy

Naoki Hosen, Yukiko Matsunaga, Kana Hasegawa, +30

Nature Medicine

Cancer ImmunosurveillanceImmunologyCellular Immune ResponseIntegrin β7Immunotherapy +3